Piper Sandler Issues Pessimistic Forecast for Cytek Biosciences (NASDAQ:CTKB) Stock Price
Cytek Biosciences (NASDAQ:CTKB – Get Free Report) had its price objective cut by research analysts at Piper Sandler from $8.50 to $8.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price objective would indicate a potential upside of 78.97% from the stock’s current price. […]
Cytek Biosciences (NASDAQ:CTKB – Get Free Report) had its price objective cut by research analysts at Piper Sandler from $8.50 to $8.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price objective would indicate a potential upside of 78.97% from the stock’s current price. […]
